A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy.
about
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer ImmunotherapyTrial Watch-Immunostimulation with cytokines in cancer therapyPrognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumabAcute myeloid leukemia targets for bispecific antibodies.A novel bispecific antibody, BiSS, with potent anti-cancer activities.One-domain CD4 Fused to Human Anti-CD16 Antibody Domain Mediates Effective Killing of HIV-1-Infected Cells.A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells.Proteolytic cleavages in the extracellular domain of receptor tyrosine kinases by membrane-associated serine proteases.Bispecific antibodies in cancer immunotherapy.Development of a bispecific antibody tetramerized through hetero-associating peptides.Tumor immunotherapy: New aspects of natural killer cells.
P2860
Q26797345-487E6267-ADEF-45F3-9DAE-E8AB9FE0DBF3Q28078725-A190DA1A-4D0B-4DE6-A0A5-1029F6E85E50Q37022365-5EBE4151-C0E0-4BF4-97E0-53103FF5F699Q39117761-279F4697-E6DC-462B-B6F5-3D77A3E11DFDQ40038526-869B2BAE-0457-4176-A17E-A80D8877CD72Q40074629-D3DDD1CD-25CE-4714-A9D3-35219AB20A72Q40612349-3CCB8916-866F-41DC-A7E1-A833CBBC45DFQ41346146-BE69D6C1-B044-46F8-9468-B3FCE4384FE1Q51309023-57D4937B-8150-4852-A22D-B86B5A28541FQ51784482-702041B5-1454-4BD3-9011-7C2C78FE189AQ55107050-77FFEE25-BD12-4176-B9EE-9F25936D48E3
P2860
A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A FcγRIII-engaging bispecific ...... eligible to antibody therapy.
@ast
A FcγRIII-engaging bispecific ...... eligible to antibody therapy.
@en
A FcγRIII-engaging bispecific ...... eligible to antibody therapy.
@nl
type
label
A FcγRIII-engaging bispecific ...... eligible to antibody therapy.
@ast
A FcγRIII-engaging bispecific ...... eligible to antibody therapy.
@en
A FcγRIII-engaging bispecific ...... eligible to antibody therapy.
@nl
prefLabel
A FcγRIII-engaging bispecific ...... eligible to antibody therapy.
@ast
A FcγRIII-engaging bispecific ...... eligible to antibody therapy.
@en
A FcγRIII-engaging bispecific ...... eligible to antibody therapy.
@nl
P2860
P50
P356
P1433
P1476
A FcγRIII-engaging bispecific ...... s eligible to antibody therapy
@en
P2093
Marc Turini
Pierre Bruhns
P2860
P304
P356
10.18632/ONCOTARGET.2093
P407
P577
2014-07-01T00:00:00Z